Clinitech Laboratory
44.00
-44.00(-100.00%)
Market Cap₹10.00 Cr
PE Ratio25.43
Company Performance:
1D-100.00%
1M-100.00%
6M-100.00%
1Y-100.00%
5Y-100.00%
View Company Insightsright
More news about Clinitech Laboratory
12Nov 25
Clinitech Laboratory Reports Mixed H1 FY2026 Results, Approves Subsidiary Formation
Clinitech Laboratory Limited announced unaudited financial results for H1 FY2026. Revenue grew 24.64% YoY to ₹508.02 lakhs, but profit after tax declined 27.25% QoQ to ₹21.41 lakhs. The company approved formation of a new subsidiary and has utilized ₹428.30 lakhs of its ₹578.30 lakhs IPO proceeds, with ₹150 lakhs remaining for diagnostic business expansion.
 no imag found
05Aug 25
Clinitech Laboratory Limited Enhances Services with New In-House Molecular Testing Department
Clinitech Laboratory Limited has announced the introduction of an in-house molecular department for all tests, enhancing its medical services. This strategic move aims to improve diagnostic capabilities, potentially offering faster turnaround times, better quality control, and a more comprehensive service offering for patients. The expansion aligns with industry trends towards integrated and advanced diagnostic services, potentially strengthening Clinitech's market position.
 no imag found
Clinitech Laboratory
44.00
-44.00
(-100.00%)
1 Year Returns:-100.00%
Industry Peers
Dr. Lal Path Labs
1,402.30
(-0.45%)
Vijaya Diagnostic Centre
1,008.90
(-0.06%)
Metropolis Healthcare
1,860.10
(-2.07%)
Krsnaa Diagnostics
642.10
(-1.09%)
Suraksha Diagnostic
281.20
(+0.29%)
3B BlackBio DX
1,617.95
(+2.84%)
Sastasundar Ventures
284.90
(-0.19%)